Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and Geographical Regions

The global AAV vector market estimated to be 3.6 billion in the current year and USD 6.0 billion by 2035, representing a CAGR of 5.3% during the forecast period.

Global AAV Market: Growth and Trends

In the last few years, the demand for gene therapies has surged owing to their potential in targeting the underlying cause of a disease at cellular level. Presently, over 2,000 gene therapies are being evaluated in different phases of clinical development. This increasing interest in such therapies has resulted in an increase in the demand for novel delivery vectors. AAV vectors have emerged the most efficient viral vectors, among the various gene delivery vectors available. In the present year, six AAV based gene therapies have been approved for various indications. The current market dynamics suggest that close to 290 players across the globe are developing AAV vector-based therapies in order to cater to their increasing demand.

The AAV technology has a history spanning over 50 years and is consistently advancing, becoming one of the most widely utilized gene delivery systems for gene therapy purposes. Additionally, due to its uncomplicated structure, and absence of disease association, AAV vector is the most favored vector for numerous medical applications. Lately, the AAV vector market has encountered competition from various viral and non-viral systems that enable the delivery of larger genetic material. Additional complexity arises from the difficulties associated with scaling up GMP AAV production processes.

Given the current trends and anticipated opportunities in the AAV viral vector sector, we anticipate that this field will experience notable growth in the near future.

Global AAV Market: Key Insights

The report delves into the current state of global AAV viral vector market and identifies potential growth opportunities within industry.

Some key findings from the report include:

Close to 635 adeno-associated viral vector-based therapies are being evaluated by stakeholders in this domain for various disease indications.
Most (42%) therapies are in preclinical stage of development, followed by those in clinical stage (30%); majority of the therapies presently use gene augmentation approach in order to treat several diseases.
Presently, close to 95 players across the globe claim to offer their services across various scale of operations in order to support the development of AAV therapies; notably, majority of these firms are based in North America.
Several stakeholders have made significant efforts in order to develop adeno-associated viral vector-based therapies, across the globe; majority of these players have been established post-2010.
55 adeno-associated viral vector technologies / platforms are currently available in the market; these can be used by various manufacturers in order to cater the increasing demand for AAV therapies.
All the technologies / platforms developed by companies engaged in this domain are focused on adeno-associated viral vectors manufacturing; of these, majority are being developed against neurological disorders.
Majority (65%) of the trials were registered in the last three years; a significant proportion of these trials are currently under early stages of research (phase I and phase II).

Mergers and acquisitions (22%) emerged as the preferred type of partnership model adopted by industry stakeholders, as it enables companies to enter new markets and expand their product portfolios.
Over 1,600 patents have been published in the adeno-associated viral vector domain since 2021; of these, over 60% of the patents have been filed in the last five years.

The future opportunity, in terms of revenues generated from marketed and late-stage therapies, is anticipated to be well distributed across different therapeutic disorders, type of therapy and route of administration.

The market is likely to witness an annualized growth of 7.7% during the forecast period owing to various benefits offered by AAV manufacturing techniques, including high target specificity and broad tissue tropism.

Report Scope:

Type of Therapy

Gene Augmentation Therapies
Gene Regulation Therapies

Therapeutic Area

Oncological Disorders
Rare Disorders
Neurological Disorders
Metabolic Disorders
Musculoskeletal Disorders
Dermatological Disorders
Infectious Diseases
Cardiovascular Disorders
Genetic Disorders
Ophthalmic Disorders
Other Disorders

Route of Administration

Intravenous Route
Subretinal Route
Intravitreal Route
Other Routes

Scale of Operation

Preclinical
Clinical
Commercial

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America and Rest of the World

Global AAV Market: Key Segments

Muscle-related Disorders Segment is Likely to Hold the Largest Market Share

In terms of therapeutic area, the market is segmented across muscle-related disorders, genetic disorders, hematological disorders, ophthalmic disorders, dermatological disorders and metabolic disorders. In the current year, the muscle-related disorders segment occupies the higher AAV vector market share (53%), owing to the increasing adoption of AAV vector-based therapies in the treatment of severe muscle disorders, specifically Duchenne muscular dystrophy (DMD) and spinal muscular atrophy.

Gene Augmentation Therapies Segment Holds the Largest Market Share

In terms of type of therapy, the global AAV vector-based therapies market is segmented across gene augmentation therapies and gene regulation therapies. In the current year, the revenues generated by the sales of gene augmentation therapies completely drive the AAV vector-based therapies industry. Further, the market is likely to witness a considerable increase in the share of gene regulation therapies, growing at a CAGR of 61% during the forecast period.

Intravenous Route Segment Holds the Largest Market Share

In terms of route of administration, the AAV vector based therapies industry is segmented across intravenous route, subretinal route, intravitreal route and other routes. In the current year, intravenous route segment occupies the highest market share due to the ability of intravenous route to deliver therapy quickly and evenly across the entire body. In addition, the market is anticipated to witness a considerable increase in the share of therapies administered via intravitreal route, growing at a CAGR of 64% during the forecast period. This is an outcome of the increasing number of AAV based therapy approvals for ophthalmic disorders, for which intravitreal route has emerged as the primary route.

Europe is likely to Propel in the AAV vector based Therapies Market in the Coming Years

This segment highlights the distribution of AAV vector based therapies market across various geographical regions, namely North America, Europe, Asia-Pacific and Latin America, and rest of the world. Our estimates suggest that North America is likely to capture the majority (~75%) of the AAV vector based therapies market share in the current year. This can be attributed to the availability of advanced healthcare infrastructure within this region to conduct a large number of clinical trials.

Example Players in the AAV Market Profiled in the Report Include:

Astellas Pharma
Charles River Laboratories
Cytiva
Lonza
Patheon pharma services
Sanofi
WuXi AppTec
Sarepta Therapeutics
Uniqure
Spark Therapeutics
PTC Therapeutics
Biomarin Pharmaceutical
Novartis

Global AAV Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global AAV vector market, focusing on key market segments, including [A] type of therapy, [B] therapeutic area, [C] route of administration, [D] scale of operation and [E] geographical regions.
Adeno-associated Viral Vector Manufacturing Market Landscape: The report features an in-depth analysis of the global AAV vector market, focusing on key market segments, including [A] status of development, [B] therapeutic area, [C] type of gene / molecule targeted, [D] type of therapy, [E] gene delivery method used, [F] route of administration, [G] special designation awarded, [H] year of establishment, [I] company size, and [J] location of headquarters.
Adeno-associated Viral Vector Manufacturing Market Technologies / Platforms Landscape: A comprehensive evaluation of adeno-associated viral vector manufacturing technologies / platforms, considering various parameters, such as [A] type of vector manufactured, [B] type of viral vector manufactured, [C] scale of operation [D] application area [E] therapeutic area, [F] year of establishment, [G] company size, and [H] location of headquarters .
Company Competitiveness Analysis: A comprehensive competitive analysis of AAV viral vector manufacturers, examining factors, such as [A] manufacturer strength and [B] product portfolio strength.
Technology Competitiveness Analysis: A comprehensive competitive analysis of AAV viral vector manufacturing technologies, examining factors, such as [A] supplier power and [B] key technology specifications.
Company Profiles: In-depth company and drug profiles of the players, focusing on [A] company overview, [B] financial information (if available), [C] drug portfolio and [D] recent developments and an informed future outlook.
Clinical Trial Analysis: An insightful analysis of clinical studies, based on several parameters, such as [A] trial registration year, [B] current status, [C] phase of development, [D], enrolled patient population [E] type of sponsor / collaborator and [F] regional distribution of trials.
Partnerships and Collaborations: An in-depth analysis of the deals inked by stakeholders in the AAV vector manufacturing market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] therapeutic area, [D] application area, [E] geographical distribution [F] most active players (in terms of number of partnerships).
Likely Partners Analysis: A detailed review of the companies with the likelihood of establishing partnerships with adeno-associated viral vector and gene therapy product manufacturers, based on several parameters, such as [A] developer strength, [B] product strength, [C] therapeutic capability and [D] pipeline strength.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the AAV vector manufacturing domain, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] regional applicability, [D] CPC symbols, [E] emerging focus areas, [F] leading industry / non-industry players and [G] patent valuation.
Start-up Health Indexing: A comprehensive analysis of the various start-ups engaged in the development of adeno-associated viral vectors-based therapies, based on relevant parameters, such as [A] number of candidates in discovery, preclinical and clinical phases of development, [B] number of patents and [C] number of partnerships established.
Outsourcing: Go / No-Go Framework: An exhaustive study of the various factors that need to be taken into consideration by adeno-associated viral vector manufacturers to facilitate decision making to manufacture their respective products in-house or engage the services of a CMO.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

SECTION I: REPORT OVERVIEW

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Classification of Vectors
6.2.1. Viral Vectors
6.2.1.1. Retrovirus Vectors
6.2.1.2. Lentivirus Vectors
6.2.1.3. Adeno-associated Viral Vectors
6.2.1.4. Adenovirus Vectors
6.2.1.5. Other Viral Vectors
6.2.1.5.1. Alphavirus
6.2.1.5.2. Foamy Virus
6.2.1.5.3. Simian Virus
6.2.1.5.4. Vaccinia Virus
6.2.1.5.5. Chimeric Viral Vectors
6.2.1.5.6. Herpes Simplex Virus
6.2.1.5.7. Sendai Virus
6.2.2. Non-Viral Vectors
6.3. Adeno-associated Viral Vectors
6.3.1. Structure and Design
6.3.2. Adeno-associated Viral Vector Life Cycle
6.3.3. Application of Adeno-associated Viral Vectors
6.3.3.1. Gene Therapy
6.3.3.2. Vaccination
6.3.4. Advantages of Adeno-associated Viral Vectors
6.3.5. Challenges Related to Adeno-associated Viral Vectors
6.4. Concluding Remarks

SECTION III: COMPETITIVE LANDSCAPE

7. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Adeno-associated Viral Vector Based Therapies: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Therapeutic Area
7.2.3. Analysis by Status of Development and Therapeutic Area
7.2.4. Analysis by Type of Gene / Molecule Targeted
7.2.5. Analysis by Type of Therapy
7.2.6. Analysis by Type of Gene Delivery Method Used
7.2.7. Analysis by Route of Administration
7.2.8. Analysis by Special Designation Awarded
7.3. Adeno-associated Viral Vector Based Therapy Developers: Overall Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region)
7.3.4. Analysis by Company Size and Location of Headquarters (Region)
7.3.5. Most Active Developers: Analysis by Number of Therapies Developed

8. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS: MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Adeno-associated Viral Vector Manufacturers: Overall Market Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Product Manufactured
8.2.5. Analysis by Type of Vector Manufactured
8.2.6. Analysis by Scale of Operation
8.2.7. Analysis by Type of Manufacturer
8.2.8. Analysis by Location of Vector Manufacturing Facility
8.2.9. Analysis by Application Area

9. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING: TECHNOLOGIES / PLATFORMS LANDSCAPE

9.1. Chapter Overview
9.2. Adeno-associated Viral Vector Manufacturing: Technologies / Platforms Landscape
9.2.1. Analysis by Type of Vector Manufactured
9.2.2. Analysis by Type of Viral Vector Manufactured
9.2.3. Analysis by Scale of Operation
9.2.4. Analysis by Application Area
9.2.5. Analysis by Therapeutic Area
9.3. Adeno-associated Viral Vector Manufacturing: Technology / Platform Providers Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Company Size and Location of Headquarters
9.3.5. Most Active Players: Analysis by Number of Technologies / Platforms

10. COMPANY COMPETITVENESS ANALYSIS: ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS

10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Overview of Peer Groups
10.5. Company Competitiveness Analysis
10.5.1. Adeno-associated viral vector manufacturers headquartered in North America
10.5.2. Adeno-associated viral vector manufacturers headquartered in Europe
10.5.3. Adeno-associated viral vector manufacturers headquartered in Asia-Pacific

11. TECHNOLOGY COMPETITVENESS ANALYSIS

11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Overview of Peer Groups
11.5. Adeno-associated Viral Vector Technologies / Platforms: Competitiveness Analysis
11.5.1. Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in North America
11.5.2. Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in Europe and Asia-Pacific

SECTION IV: COMPANY PROFILES

12. MARKETED DRUG PROFILES

12.1. Chapter Overview
12.2. Elevidys (Developed by Sarepta Therapeutics)
12.2.1. Company Overview
12.2.2. Development Timeline
12.2.3. Mechanism of Action and Vector Used
12.2.4. Manufacturing, Dosage and Sales
12.2.5. Target Indication
12.2.6. Current Status of Development
12.3. Hemgenix (Developed by Uniqure)
12.4. Kebilidi (Developed by PTC Therapeutics)
12.5. Luxturna (Developed by Spark Therapeutics)
12.6. Roctavian (Developed by Biomarin Pharmaceutical)
12.7. Zolgensma (Developed by Novartis)

13. COMPANY PROFILES: LEADING ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS

13.1. Chapter Overview
13.2. Astellas Pharma
13.2.1. Company Overview
13.2.2. Financial Information
13.2.3. Vector Manufacturing Related Capabilities
13.2.4. Recent Developments and Future Outlook
13.3. Charles River Laboratories
13.4. Cytiva
13.5. Lonza
13.6. Patheon Pharma Services
13.7. Sanofi
13.8. Wuxi AppTec

SECTION V: MARKET TRENDS

14. CLINICAL TRIAL ANALYSIS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Adeno-associated Viral Vector Based Therapies: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis of Patients Enrolled by Trial Registration Year
14.3.3. Analysis by Trial Phase
14.3.4. Analysis of Patients Enrolled by Trial Phase
14.3.5. Analysis by Trial Status
14.3.6. Analysis of Patients Enrolled by Trial Status
14.3.7. Analysis by Target Patient Population
14.3.8. Analysis by Patient Gender
14.3.9. Analysis by Type of Sponsor / Collaborator14.3.10. Analysis by Study Design
14.3.10.1. Analysis by Type of Patient Allocation Model Used
14.3.10.2. Analysis by Type of Trial Masking Adopted
14.3.10.3. Analysis by Type of Trial Intervention Model
14.3.10.4. Analysis by Trial Purpose
14.3.11. Most Active Players: Analysis by Number of Clinical Trials Sponsored / Collaborated
14.3.12. Analysis by Geography
14.3.12.1. Analysis of Clinical Trials by Geography
14.3.12.2. Analysis of Clinical Trials by Geography and Trial Status
14.3.12.3. Analysis of Patients Enrolled by Geography and Trial Status
14.3.12.4. Analysis of Clinical Trials by Geography, Trial Status and Trial Phase

15. PARTNERSHIPS AND COLLABORATIONS

15.1. Chapter Overview
15.2. Partnership Models
15.3. Adeno-associated Viral Vector Based Therapy Developers: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Year of Partnership and Type of Partner
15.3.5. Analysis by Type of Partnership and Type of Partner
15.3.6. Analysis by Therapeutic Area
15.3.7. Most Active Players: Analysis by Number of Partnerships
15.3.8. Analysis by Geography
15.3.8.1. Analysis by Country
15.3.8.2. Analysis by Region
15.4. Adeno-associated Viral Vector Manufacturers: Partnerships and Collaborations
15.4.1. Analysis by Year of Partnership
15.4.2. Analysis by Type of Partnership
15.4.3. Analysis by Year and Type of Partnership
15.4.4. Analysis by Year of Partnership and Type of Partner
15.4.5. Analysis by Type of Partnership and Type of Partner
15.4.6. Analysis by Therapeutic Area
15.4.7. Analysis by Application Area
15.4.8. Most Active Players: Analysis by Number of Partnerships
15.4.9. Analysis by Geography
15.4.9.1. Analysis by Country
15.4.9.2. Analysis by Region

16. LIKELY PARTNER ANALYSIS

16.1. Chapter Overview
16.2. Adeno-associated Viral Vector Based Therapy Developers: Likely Partners
16.2.1. Methodology and Key Parameters
16.2.2. Adeno-associated Viral Vector Based Therapy Developers: Likely Partner Analysis
16.2.2.1. Most Likely Partners
16.2.2.2. Likely Partners
16.2.2.3. Less Likely Partners
16.2.2.4. Least Likely Partners

17. PATENT ANALYSIS

17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Adeno-associated Viral Vector Market: Patent Analysis
17.3.1. Analysis by Patent Application Year
17.3.2. Analysis by Patent Publication Year
17.3.3. Analysis by Type of Patent and Publication Year
17.3.4. Analysis by Patent Jurisdiction
17.3.5. Analysis by CPC Symbols
17.3.6. Analysis by Type of Applicant
17.3.7. Leading Industry Players: Analysis by Number of Patents
17.3.8. Leading Non-Industry Players: Analysis by Number of Patents
17.3.9. Leading Patent Assignees: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
17.4.1. Analysis by Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations

18. START-UP HEALTH INDEXING

18.1. Chapter Overview
18.2. Start-ups Developing Adeno-associated Viral Vector Based Therapies
18.2.1. Analysis by Location of Headquarters
18.3. Benchmarking of Start-ups
18.3.1. Analysis by Pipeline Strength
18.3.2. Analysis by Pipeline Maturity
18.3.3. Analysis by Indication Diversity
18.3.4. Analysis by Patent Strength
18.3.5. Analysis by Partnership Activity
18.3.6. Start-ups Health Indexing: Roots Analysis Perspective

19. OUTSOURCING: GO / NO-GO FRAMEWORK

19.1. Chapter Overview
19.2. Outsourcing: Go / No-Go Framework
19.3. Adeno-associated Viral Vector Developers Outsourcing: Go / No-Go Framework
19.3.1. Key Assumptions and Parameters
19.3.2. Methodology
19.3.3. Results and Interpretations
19.3.3.1. Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Small Companies
19.3.3.2. Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Mid-sized Companies
19.3.3.3. Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Large Companies
19.4. Concluding Remarks

SECTION VI: MARKET OPPORTUNITY ANALYSIS

20. GLOBAL ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPEUTICS MARKET

20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Global Adeno-associated Viral Vector Based Therapeutics Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.3.1. Scenario Analysis
20.3.1.1. Conservative Scenario
20.3.1.2. Optimistic Scenario
20.4. Key Market Segmentations

21. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPEUTICS MARKET, BY THERAPEUTIC AREA

21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Therapeutic Area
21.3.1. Adeno-associated Viral Vector Based Therapeutics Market for Muscle-related Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.2. Adeno-associated Viral Vector Based Therapeutics Market for Genetic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.3.3. Adeno-associated Viral Vector Based Therapeutics Market for Hematological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
21.3.4. Adeno-associated Viral Vector Based Therapeutics Market for Ophthalmic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.3.5. Adeno-associated Viral Vector Based Therapeutics Market for Dermatological Disorders: Forecasted Estimates (till 2035)
21.3.6. Adeno-associated Viral Vector Based Therapeutics Market for Metabolic Disorders: Forecasted Estimates (till 2035)

22. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPEUTICS MARKET, BY TYPE OF THERAPY

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Type of Therapy
22.3.1. Adeno-associated Viral Vector Based Therapeutics Market for Gene Augmentation Therapies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
22.3.2. Adeno-associated Viral Vector Based Therapeutics Market for Gene Regulation Therapies, Forecasted Estimates (till 2035)

23. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Route of Administration
23.3.1. Adeno-associated Viral Vector Based Therapeutics Market for Intravenous Route: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
23.3.2. Adeno-associated Viral Vector Based Therapeutics Market for Subretinal Route: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
23.3.3. Adeno-associated Viral Vector Based Therapeutics Market for Intravitreal Route: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
23.3.4. Adeno-associated Viral Vector Based Therapeutics Market for Other Routes: Historical Trends (since 2022) and Forecasted Estimates (till 2035)

24. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Geographical Regions
24.3.1. Adeno-associated Viral Vector Based Therapeutics Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.3.2. Adeno-associated Viral Vector Based Therapeutics Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.3.3. Adeno-associated Viral Vector Based Therapeutics Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.3.4. Adeno-associated Viral Vector Based Therapeutics Market in Latin America and Rest of the World: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

25. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPEUTICS MARKET: SALES FORECAST OF THERAPIES

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Commercialized Adeno-associated Vector Based Therapeutics: Sales Forecast
25.3.1. Luxturna
25.3.1.1. Sales Forecast
25.3.1.2. Net Present Value
25.3.1.3. Value Creation Analysis
25.3.2. Hemgenix
25.3.2.1. Sales Forecast
25.3.2.2. Net Present Value
25.3.2.3. Value Creation Analysis
25.3.3. Zolgensma
25.3.3.1. Sales Forecast
25.3.3.2. Net Present Value
25.3.3.3. Value Creation Analysis
25.3.4. Roctavian
25.3.4.1. Sales Forecast
25.3.4.2. Net Present Value
25.3.4.3. Value Creation Analysis
25.3.5. Elevidys
25.3.5.1. Sales Forecast
25.3.5.2. Net Present Value
25.3.5.3. Value Creation Analysis
25.3.6. Upstaza
25.3.6.1. Sales Forecast
25.3.6.2. Net Present Value
25.3.6.3. Value Creation Analysis
25.3.7. EB 101
25.3.7.1. Sales Forecast
25.3.7.2. Net Present Value
25.3.7.3. Value Creation Analysis
25.3.8. BBM H901
25.3.8.1. Sales Forecast
25.3.8.2. Net Present Value
25.3.8.3. Value Creation Analysis
25.4. Phase III Adeno-Associated Vector Based Therapeutics: Sales Forecast
25.4.1. AGTC 501
25.4.1.1. Sales Forecast
25.4.2. Lumevoq
25.4.2.1. Sales Forecast
25.4.3. NFS-01
25.4.3.1. Sales Forecast
25.4.4. RGX-314
25.4.4.1. Sales Forecast
25.4.5. SPK-8011
25.4.5.1. Sales Forecast
25.4.6. Giroctocogene fitelparvovec
25.4.6.1. Sales Forecast
25.4.7. RGX-121
25.4.7.1. Sales Forecast
25.4.7.2. Net Present Value
25.4.7.3. Value Creation Analysis
25.4.8. DTx-401
25.4.8.1. Sales Forecast
25.4.9. DTx-301
25.4.9.1. Sales Forecast
25.4.10. ABO-102
25.4.10.1. Sales Forecast
25.4.11. AAV-RPE65
25.4.11.1. Sales Forecast
25.4.12. Ixoberogene Soroparvovec
25.4.12.1. Sales Forecast
25.4.13. OCU400
25.4.13.1. Sales Forecast

26. GLOBAL ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET

26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Global Adeno-associated Viral Vector Manufacturing Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.3.1. Scenario Analysis
26.3.1.1. Conservative Scenario
26.3.1.2. Optimistic Scenario
26.4. Key Market Segmentations

27. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Stage of Development, 2021, 2025 and 2035
27.3.1. Adeno-associated Viral Vector Manufacturing Market for Commercial Stage Products: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.3.2. Adeno-associated Viral Vector Manufacturing Market for Clinical Stage Products: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.3.3. Adeno-associated Viral Vector Manufacturing Market for Preclinical Stage Products: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Therapeutic Area, 2021, 2025 and 2035
28.3.1. Adeno-associated Viral Vector Manufacturing Market for Oncological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.2. Adeno-associated Viral Vector Manufacturing Market for Rare Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.3. Adeno-associated Viral Vector Manufacturing Market for Musculoskeletal Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.4. Adeno-associated Viral Vector Manufacturing Market for Genetic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.5. Adeno-associated Viral Vector Manufacturing Market for Hematological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.6. Adeno-associated Viral Vector Manufacturing Market for Neurological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.7. Adeno-associated Viral Vector Manufacturing Market for Metabolic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.8. Adeno-associated Viral Vector Manufacturing Market for Sensory Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.9. Adeno-associated Viral Vector Manufacturing Market for Ophthalmic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3.10. Adeno-associated Viral Vector Manufacturing Market for Dermatological Disorders: Historical Trends (since 2025) and Forecasted Estimates (till 2035)
28.3.11. Adeno-associated Viral Vector Manufacturing Market for Others: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Geographical Regions, 2021, 2025 and 2035
29.3.1. Adeno-associated Viral Vector Manufacturing Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3.2. Adeno-associated Viral Vector Manufacturing Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3.3. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3.4. Adeno-associated Viral Vector Manufacturing Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3.5. Adeno-associated Viral Vector Manufacturing Market in Latin America and Rest of the World: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.4. Market Dynamics Assessment
29.4.1. Penetration Growth (P-G) Matrix

30. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET BY COMMERCIAL, CLINICAL AND PRECLINICAL STAGE PRODUCTS

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Key Market Segmentations
30.4. Adeno-associated Viral Vector Manufacturing Market for Commercial Stage Products: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.4.1. Adeno-associated Viral Vector Manufacturing Market for Commercial Stage Products: Distribution by Therapeutic Area
30.4.2. Adeno-associated Viral Vector Manufacturing Market for Commercial Stage Products: Distribution by Route of Administration
30.4.3. Adeno-associated Viral Vector Manufacturing Market for Commercial Stage Products: Distribution by Geographical Regions
30.5. Adeno-associated Viral Vector Manufacturing Market for Clinical Stage Products: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.5.1. Adeno-associated Viral Vector Manufacturing Market for Clinical Stage Products: Distribution by Phase of Development
30.5.2. Adeno-associated Viral Vector Manufacturing Market for Clinical Stage Products: Distribution by Therapeutic Area
30.5.3. Adeno-associated Viral Vector Manufacturing Market for Clinical Stage Products: Distribution by Geographical Regions
30.6. Adeno-associated Viral Vector Manufacturing Market for Preclinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.6.1. Adeno-associated Viral Vector Manufacturing Market for Preclinical Stage Products: Distribution by Therapeutic Area
30.6.2. Adeno-associated Viral Vector Manufacturing Market for Preclinical Stage Products: Distribution by Animal Model Used
30.6.3. Adeno-associated Viral Vector Manufacturing Market for Preclinical Stage Products: Distribution by Geographical Regions

SECTION VII: OTHER EXCLUSIVE INSIGHTS31. CONCLUDING INSIGHTS32. EXECUTIVE INSIGHTSSECTION VIII: APPENDICES33. APPENDIX I: TABULATED DATA34. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Classification of Vectors
Figure 6.2 Structure of Adeno-associated Viral Vector
Figure 6.3 Lytic Cycle of Adeno-associated Viral Vector
Figure 6.4 Lysogenic Cycle of Adeno-associated Viral Vector
Figure 7.1 Adeno-associated Viral Vector Based Therapies: Distribution by Status of Development
Figure 7.2 Adeno-associated Viral Vector Based Therapies: Distribution by Therapeutic Area
Figure 7.3 Adeno-associated Viral Vector Based Therapies: Distribution by Status of Development and Therapeutic Area
Figure 7.4 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Gene / Molecule Targeted
Figure 7.5 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Therapy
Figure 7.6 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Gene Delivery Method Used
Figure 7.7 Adeno-associated Viral Vector Based Therapies: Distribution by Route of Administration
Figure 7.8 Adeno-associated Viral Vector Based Therapies: Distribution by Special Designation Awarded
Figure 7.9 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Establishment
Figure 7.10 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Company Size
Figure 7.11 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Location of Headquarters (Region)
Figure 7.12 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.13 Most Active Developers: Distribution by Number of Therapies Developed
Figure 8.1 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Establishment
Figure 8.2 Adeno-associated Viral Vector Manufacturers: Distribution by Company Size
Figure 8.3 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Headquarters
Figure 8.4 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Product Manufactured
Figure 8.5 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Vector Manufactured
Figure 8.6 Adeno-associated Viral Vector Manufacturers: Distribution by Scale of Operation
Figure 8.7 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Manufacturer
Figure 8.8 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Manufacturer and Company Size
Figure 8.9 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Manufacturing Facilities (Region)
Figure 8.10 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Manufacturing Facilities (Country)
Figure 8.11 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Figure 9.1 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Vector Manufactured
Figure 9.2 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Viral Vector Manufactured
Figure 9.3 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Scale of Operation
Figure 9.4 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Application Area
Figure 9.5 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Therapeutic Area
Figure 9.6 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Year of Establishment
Figure 9.7 Adeno-associated Viral Vector Technology Platform Providers: Distribution by Company Size
Figure 9.8 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Location of Headquarters (Region)
Figure 9.9 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Location of Headquarters (Country)
Figure 9.10 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Company Size and Location of Headquarters
Figure 9.11 Most Active Players: Distribution by Number of Technologies / Platforms
Figure 10.1 Company Competitiveness Analysis: Overview of Peer Group I
Figure 10.2 Company Competitiveness Analysis: Overview of Peer Group II
Figure 10.3 Company Competitiveness Analysis: Overview of Peer Group III
Figure 10.4 Company Competitiveness Analysis: Adeno-associated Viral Vector Manufacturers Headquartered in North America (Peer Group I)
Figure 10.5 Company Competitiveness Analysis: Adeno-associated Viral Vector Manufacturers Headquartered in Europe (Peer Group II)
Figure 10.6 Company Competitiveness Analysis: Adeno-associated Viral Vector Manufacturers Headquartered in Asia-Pacific (Peer Group III)
Figure 11.1 Technology Competitiveness Analysis: Overview of Peer Group I
Figure 11.2 Technology Competitiveness Analysis: Overview of Peer Group II
Figure 11.3 Technology Competitiveness Analysis: Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in North America (Peer Group I)
Figure 11.4 Technology Competitiveness Analysis: Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in Europe and Asia-Pacific (Peer Group II)
Figure 12.1 Elevidys: Development Timeline
Figure 12.2 Hemgenix: Development Timeline
Figure 12.3 KEBILIDI: Development Timeline
Figure 12.4 Luxturna: Development Timeline
Figure 12.5 Roctavian: Development Timeline
Figure 12.6 Zolgensma: Development Timeline
Figure 13.1 Astellas Pharma: Annual Revenues, since FY 2021 (YEN Billion)
Figure 13.2 Charles River Laboratories: Annual Revenues, since FY 2021 (USD Billion)
Figure 13.3 Lonza: Annual Revenues, since FY 2021 (CHF Billion)
Figure 13.4 Thermo Fisher Scientific (Parent Company of Patheon Pharma Services): Annual Revenues, since FY 2021 (USD Billion)
Figure 13.5 Sanofi: Annual Revenues, since FY 2021 (EUR Billion)
Figure 13.6 WuXi AppTec: Annual Revenues, since FY 2021 (RMB Billion)
Figure 14.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2020
Figure 14.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2020
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Figure 14.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Figure 14.7 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Status
Figure 14.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 14.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 14.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.11 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 14.12 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Figure 14.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 14.14 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 14.15 Most Active Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Figure 14.16 Most Active Non-Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Figure 14.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 14.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 14.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 14.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography, Trial Status and Trial Phase
Figure 15.1 Adeno-associated Viral Vector Based Therapy Developers: Cumulative Year-wise Trend, since 2017
Figure 15.2 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Type of Partnership
Figure 15.3 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year and Type of Partnership, since 2022
Figure 15.4 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Partnership and Type of Partner, since 2022
Figure 15.5 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Type of Partnership and Type of Partner
Figure 15.6 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Therapeutic Area
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Country
Figure 15.9 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Region
Figure 15.10 Adeno-associated Viral Vector Manufacturers: Cumulative Year-wise Trend, since 2017
Figure 15.11 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partnership
Figure 15.12 Adeno-associated Viral Vector Manufacturers: Distribution by Year and Type of Partnership, since 2022
Figure 15.13 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Partnership and Type of Partner, since 2022
Figure 15.14 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partnership and Type of Partner
Figure 15.15 Adeno-associated Viral Vector Manufacturers: Distribution by Therapeutic Area
Figure 15.16 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Figure 15.17 Most Active Players: Distribution by Number of Partnerships
Figure 15.18 Adeno-associated Viral Vector Manufacturers: Distribution by Country
Figure 15.19 Adeno-associated Viral Vector Manufacturers: Distribution by Region
Figure 17.1 Patent Analysis: Distribution by Type of Patent
Figure 17.2 Patent Analysis: Distribution by Patent Application Year, since pre-2019
Figure 17.3 Patent Analysis: Distribution by Publication Year, since 2021
Figure 17.4 Patent Analysis: Type of Patent and Publication Year, since 2021
Figure 17.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 17.6 Patent Analysis: Distribution by CPC Symbols
Figure 17.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, since 2021
Figure 17.8 Leading Industry Players: Distribution by Number of Patents
Figure 17.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 17.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 17.11 Patent Benchmarking Analysis: Distribution by Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 17.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 17.13 Patent Valuation: Distribution of Patents by Age
Figure 17.14 AAV Vector Market: Patent Valuation
Figure 18.1 Start-up Health Indexing: Distribution by Location of Headquarters
Figure 18.2 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 18.3 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 18.4 Start-up Health Indexing: Distribution by Indication Diversity
Figure 18.5 Start-up Health Indexing: Distribution by Patent Strength
Figure 18.6 Start-up Health Indexing: Distribution by Partnership Activity
Figure 18.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 18.8 Leading Start-ups: Spider Web Analysis
Figure 19.1 Outsourcing: Go / No Go Framework
Figure 19.2 Outsourcing: Go / No Go Framework for Adeno-associated Viral Vector Based Therapy Developers
Figure 19.3 Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Small Companies
Figure 19.4 Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Mid-sized Companies
Figure 19.5 Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Large Companies
Figure 20.1 Global Adeno-associated Viral Vector Based Therapeutics Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.2 Global Adeno-associated Viral Vector Based Therapeutics Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 20.3 Adeno-associated Viral Vector Based Therapeutics Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 21.1 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Therapeutic Area
Figure 21.2 Adeno-associated Viral Vector Based Therapeutics Market for Muscle-related Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Adeno-associated Viral Vector Based Therapeutics Market for Genetic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.4 Adeno-associated Viral Vector Based Therapeutics Market for Hematological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.5 Adeno-associated Viral Vector Based Therapeutics Market for Ophthalmic Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.6 Adeno-associated Viral Vector Based Therapeutics Market for Dermatological Disorders: Forecasted Estimates (till 2035) (USD Million)
Figure 21.7 Adeno-associated Viral Vector Based Therapeutics Market for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.1 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Type of Therapy
Figure 22.2 Adeno-associated Viral Vector Based Therapeutics Market for Gene Augmentation Therapies: Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Adeno-associated Viral Vector Based Therapeutics Market for Gene Regulation Therapy: Forecasted Estimates (till 2035) (USD Million)
Figure 23.1 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Route of Administration
Figure 23.2 Adeno-associated Viral Vector Based Therapeutics Market for Intravenous Route: Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.3 Adeno-associated Viral Vector Based Therapeutics Market for Subretinal Route: Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.4 Adeno-associated Viral Vector Based Therapeutics Market for Intravitreal Route: Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.5 Adeno-associated Viral Vector Based Therapeutics Market for Other Routes: Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.1 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Geographical Regions
Figure 24.2 Adeno-associated Viral Vector Based Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.3 Adeno-associated Viral Vector Based Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.4 Adeno-associated Viral Vector Based Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.5 Adeno-associated Viral Vector Based Manufacturing Market in Latin America and Rest of the World, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.1 Adeno-associated Vector Based Therapeutics Market: Luxturna Sales Forecast, till 2035 (USD Million)
Figure 25.2 Adeno-associated Vector Based Therapeutics Market: Hemgenix Sales Forecast, till 2035 (USD Million)
Figure 25.3 Adeno-associated Vector Based Therapeutics Market: Zolgensma Sales Forecast, till 2035 (USD Million)
Figure 25.4 Adeno-associated Vector Based Therapeutics Market: Roctavian Sales Forecast, till 2035 (USD Million)
Figure 25.5 Adeno-associated Vector Based Therapeutics Market: Elevidys Sales Forecast, till 2035 (USD Million)
Figure 25.6 Adeno-associated Vector Based Therapeutics Market: Upstaza Sales Forecast, till 2035 (USD Million)
Figure 25.7 Adeno-associated Vector Based Therapeutics Market: EB 101 Sales Forecast, till 2035 (USD Million)
Figure 25.8 Adeno-associated Vector Based Therapeutics Market: BBM H901 Sales Forecast, till 2035 (USD Million)
Figure 25.9 Adeno-associated Vector Based Therapeutics Market: AGTC 501 Sales Forecast, till 2035 (USD Million)
Figure 25.10 Adeno-associated Vector Based Therapeutics Market: Lumevoq Sales Forecast, till 2025 (USD Million)
Figure 25.11 Adeno-associated Vector Based Therapeutics Market: NFS-01 Sales Forecast, till 2035 (USD Million)
Figure 25.12 Adeno-associated Vector Based Therapeutics Market: RGX-314 Sales Forecast, till 2035 (USD Million)
Figure 25.13 Adeno-associated Vector Based Therapeutics Market: SPK-8011 Sales Forecast, till 2035 (USD Million)
Figure 25.14 Adeno-associated Vector Based Therapeutics Market: Giroctocogene fitelparvovec Sales Forecast, till 2035 (USD Million)
Figure 25.15 Adeno-associated Vector Based Therapeutics Market: RGX-121 Sales Forecast, till 2035 (USD Million)
Figure 25.16 Adeno-associated Vector Based Therapeutics Market: DTx-401 Sales Forecast, till 2035 (USD Million)
Figure 25.17 Adeno-associated Vector Based Therapeutics Market: DTx-301 Sales Forecast, till 2035 (USD Million)
Figure 25.18 Adeno-associated Vector Based Therapeutics Market: ABO-102 Sales Forecast, till 2035 (USD Million)
Figure 25.19 Adeno-associated Vector Based Therapeutics Market: AAV-RPE65 Sales Forecast, till 2035 (USD Million)
Figure 25.20 Adeno-associated Vector Based Therapeutics Market: Ixoberogene Soroparvovec Sales Forecast, till 2035 (USD Million)
Figure 25.21 Adeno-associated Vector Based Therapeutics Market: OCU400 Sales Forecast, till 2035 (USD Million)
Figure 26.1 Global Adeno-associated Viral Vector Based Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.2 Global Adeno-associated Viral Vector Based Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 26.3 Global Adeno-associated Viral Vector Based Manufacturing Market Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 27.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Stage of Development
Figure 27.2 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.3 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.4 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Therapeutic Area, 2021, 2025 and 2035
Figure 28.2 Adeno-associated Viral Vector Based Manufacturing Market for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.3 Adeno-associated Viral Vector Based Manufacturing Market for Rare Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.4 Adeno-associated Viral Vector Based Manufacturing Market for Musculoskeletal Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.5 Adeno-associated Viral Vector Based Manufacturing Market for Genetic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.6 Adeno-associated Viral Vector Based Manufacturing Market for Hematological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.7 Adeno-associated Viral Vector Based Manufacturing Market for Neurological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.8 Adeno-associated Viral Vector Based Manufacturing Market for Metabolic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.9 Adeno-associated Viral Vector Based Manufacturing Market for Sensory Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.10 Adeno-associated Viral Vector Based Manufacturing Market for Ophthalmic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.11 Adeno-associated Viral Vector Based Manufacturing Market for Dermatological Disorders, Forecasted Estimates (till 2035) (USD Million)
Figure 28.12 Adeno-associated Viral Vector Based Manufacturing Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Geographical Regions
Figure 29.2 Adeno-associated Viral Vector Based Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.3 Adeno-associated Viral Vector Based Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.4 Adeno-associated Viral Vector Based Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.5 Adeno-associated Viral Vector Based Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.6 Adeno-associated Viral Vector Based Manufacturing Market in Latin America and Rest of the World, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.7 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 30.1 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.2 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products: Distribution by Therapeutic Area
Figure 30.3 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products: Distribution by Route of Administration
Figure 30.4 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products: Distribution by Geographical Regions
Figure 30.5 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.6 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products: Distribution by Phase of Development
Figure 30.7 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products: Distribution by Therapeutic Area
Figure 30.8 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products: Distribution by Geographical Regions
Figure 30.9 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.10 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products: Distribution by Therapeutic Area
Figure 30.11 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products: Distribution by Animal Model Used
Figure 30.12 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products: Distribution by Geographical Regions
Figure 31.1 Concluding Remarks: Adeno-Associated Viral Vector Based Therapies Market Landscape
Figure 31.2 Concluding Remarks: Adeno-Associated Viral Vector Based Manufacturers and Technologies / Platforms Landscape
Figure 31.3 Concluding Remarks: Clinical Trial Analysis
Figure 31.4 Concluding Remarks: Partnerships and Collaborations
Figure 31.5 Concluding Remarks: Patent Analysis
Figure 31.6 Concluding Remarks: Adeno-Associated Viral Vector-based Therapy Market Forecast
Figure 31.7 Concluding Remarks: Adeno-Associated Viral Vector Manufacturing Market Forecast

LIST OF TABLES

Table 7.1 Adeno-associated Viral Vector Based Therapy Market: Information on Developer, Status of Development, Target Indication, Therapeutic Area, Type of Gene / Molecule Targeted, Gene Delivery Method, Route of Administration and Type of Therapy
Table 7.2 Adeno-associated Viral Vector Based Therapy Market: Information on Special Designation Awarded
Table 7.3 List of Adeno-associated Viral Vector Based Therapy Developers
Table 8.1 Adeno-associated Viral Vector Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Type of Product Manufactured
Table 8.2 Adeno-associated Viral Vector Manufacturers: Information on Type of Vector Manufactured, Scale of Operation and Type of Manufacturer
Table 8.3 Adeno-associated Viral Vector Manufacturers: Information on Location of Manufacturing Facility and Application Area
Table 9.1 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Information on Technology Provider, Type of Vector Manufactured and Type of Viral Vector Manufactured
Table 9.2 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Information on Scale of Operation, Application Area and Therapeutic Area
Table 9.3 Adeno-associated Viral Vector Manufacturing Technology / Platform Providers: Information on Year of Establishment, Company Size and Headquarters
Table 10.1 Company Competitiveness Scores Allotted to Manufacturers Headquartered in North America (Peer Group I)
Table 10.2 Company Competitiveness Scores Allotted to Manufacturers based in Europe (Peer Group II)
Table 10.3 Company Competitiveness Scores Allotted to Manufacturers based in Asia-Pacific (Peer Group III)
Table 12.1 List of Marketed Adeno-associated Vector Based Therapies Profiled
Table 12.2 Sarepta Therapeutics: Company Overview
Table 12.3 Elevidys: Current Status of Development
Table 12.4 uniQure: Company Overview
Table 12.5 Hemgenix: Current Status of Development
Table 12.6 PTC Therapeutics: Company Overview
Table 12.7 KEBILIDI: Current Status of Development
Table 12.8 Spark Therapeutics: Company Overview
Table 12.9 Luxturna: Current Status of Development
Table 12.10 BioMarin Pharmaceutical: Company Overview
Table 12.11 Roctavian: Current Status of Development
Table 12.12 Novartis: Company Overview
Table 12.13 Zolgensma: Current Status of Development
Table 13.1 AAV Vector Service Providers: List of Companies Profiled
Table 13.2 Astellas Pharma: Company Overview
Table 13.3 Astellas Pharma: Vector Manufacturing Related Capabilities
Table 13.4 Astellas Pharma: Recent Developments and Future Outlook
Table 13.5 Charles River Laboratories: Company Overview
Table 13.6 Charles River Laboratories: Vector Manufacturing Related Capabilities
Table 13.7 Charles River Laboratories: Recent Developments and Future Outlook
Table 13.8 Cytiva: Company Overview
Table 13.9 Cytiva: Vector Manufacturing Related Capabilities
Table 13.10 Cytiva: Recent Developments and Future Outlook
Table 13.11 Lonza: Company Overview
Table 13.12 Lonza: Vector Manufacturing Related Capabilities
Table 13.13 Lonza: Recent Developments and Future Outlook
Table 13.14 Patheon Pharma Services: Company Overview
Table 13.15 Patheon Pharma Services: Vector Manufacturing Related Capabilities
Table 13.16 Thermo Fisher Scientific (Parent Company of Patheon Pharma Services): Recent Developments and Future Outlook
Table 13.17 Sanofi: Company Overview
Table 13.18 Sanofi: Vector Manufacturing Related Capabilities
Table 13.19 Sanofi: Recent Developments and Future Outlook
Table 13.20 WuXi AppTec: Company Overview
Table 13.21 WuXi AppTec: Vector Manufacturing Related Capabilities
Table 13.22 WuXi AppTec: Recent Developments and Future Outlook
Table 15.1 Adeno-associated Viral Vector Based Therapy Developers: List of Partnerships and Collaborations, since 2022
Table 15.2 Adeno-associated Viral Vector Based Therapy Developers: Information on Therapeutic Area
Table 15.3 Adeno-associated Viral Vector Based Therapy Developers: Information on Type of Agreement
Table 15.4 Adeno-associated Viral Vector Manufacturers: List of Partnerships and Collaborations, since 2022
Table 15.5 Adeno-associated Viral Vector Manufacturers: Information on Therapeutic Area
Table 15.6 Adeno-associated Viral Vector Manufacturers: Information on Application Area
Table 15.7 Adeno-associated Viral Vector Manufacturers: Information on Type of Agreement
Table 16.1 Adeno-associated Viral Vector Based Therapy Manufacturers: Most Likely Partners
Table 16.2 Adeno-associated Viral Vector Based Therapy Manufacturers: Likely Partners
Table 16.3 Adeno-associated Viral Vector Based Therapy Manufacturers: Less Likely Partners
Table 16.4 Adeno-associated Viral Vector Based Therapy Manufacturers: Least Likely Partners
Table 17.1 Patent Analysis: Top CPC Sections
Table 17.2 Patent Analysis: Top CPC Symbols
Table 17.3 Patent Analysis: Top CPC Codes
Table 17.4 Patent Analysis: Summary of Benchmarking Analysis
Table 17.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 18.1 List of Start-ups Developing Adeno-associated Viral Vectors
Table 25.1 Luxturna: Net Present Value (USD Million)
Table 25.2 Luxturna: Value Creation Analysis (USD Million)
Table 25.3 Hemgenix: Net Present Value (USD Million)
Table 25.4 Hemgenix: Value Creation Analysis (USD Million)
Table 25.5 Zolgensma: Net Present Value (USD Million)
Table 25.6 Zolgensma: Value Creation Analysis (USD Million)
Table 25.7 Roctavian: Net Present Value (USD Million)
Table 25.8 Roctavian: Value Creation Analysis (USD Million)
Table 25.9 Elevidys: Net Present Value (USD Million)
Table 25.10 Elevidys: Value Creation Analysis (USD Million)
Table 25.11 Upstaza: Net Present Value (USD Million)
Table 25.12 Upstaza: Value Creation Analysis (USD Million)
Table 25.13 EB 101: Net Present Value (USD Million)
Table 25.14 EB 101: Value Creation Analysis (USD Million)
Table 25.15 BBM H901: Net Present Value (USD Million)
Table 25.16 BBM H901: Value Creation Analysis (USD Million)
Table 25.17 RGX-121: Net Present Value (USD Million)
Table 25.18 RGX-121: Value Creation Analysis (USD Million)
Table 32.1 Andelyn Bioscience: Organization Snapshot
Table 32.2 University of Florida: Organization Snapshot
Table 32.3 Boston College: Organization Snapshot
Table 33.1 Adeno-associated Viral Vector Based Therapies: Distribution by Status of Development
Table 33.2 Adeno-associated Viral Vector Based Therapies: Distribution by Therapeutic Area
Table 33.3 Adeno-associated Viral Vector Based Therapies: Distribution by Status of Development and Therapeutic Area
Table 33.4 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Gene / Molecule Targeted
Table 33.5 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Therapy
Table 33.6 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Gene Delivery Method Used
Table 33.7 Adeno-associated Viral Vector Based Therapies: Distribution by Route of Administration
Table 33.8 Adeno-associated Viral Vector Based Therapies: Distribution by Special Designation Awarded
Table 33.9 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Establishment
Table 33.10 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Company Size
Table 33.11 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Location of Headquarters (Region)
Table 33.12 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 33.13 Most Active Developers: Distribution by Number of Therapies Developed
Table 33.14 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Establishment
Table 33.15 Adeno-associated Viral Vector Manufacturers: Distribution by Company Size
Table 33.16 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Headquarters (Region)
Table 33.17 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Product Manufactured
Table 33.18 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Vector Manufactured
Table 33.19 Adeno-associated Viral Vector Manufacturers: Distribution by Scale of Operation
Table 33.20 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Manufacturer
Table 33.21 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Manufacturing Facilities (Region)
Table 33.22 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Manufacturing Facilities (Country)
Table 33.23 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Table 33.24 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Vector Manufactured
Table 33.25 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Viral Vector Manufactured
Table 33.26 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Scale of Operation
Table 33.27 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Application Area
Table 33.28 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Therapeutic Area
Table 33.29 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Year of Establishment
Table 33.30 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Company Size
Table 33.31 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Location of Headquarters (Region)
Table 33.32 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Location of Headquarters (Country)
Table 33.33 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Company Size and Location of Headquarters
Table 33.34 Most Active Players: Distribution by Number of Technologies / Platforms
Table 33.35 Astellas Pharma: Annual Revenues, since FY 2021 (YEN Billion)
Table 33.36 Charles River Laboratories: Annual Revenues, since FY 2021 (USD Billion)
Table 33.37 Lonza: Annual Revenues, since FY 2021 (CHF Billion)
Table 33.38 Thermo Fisher Scientific (Parent Company of Patheon Pharma Services): Annual Revenues, since FY 2021 (USD Billion)
Table 33.39 Sanofi: Annual Revenues, since FY 2021 (EUR Billion)
Table 33.40 WuXi AppTec: Annual Revenues, since FY 2021 (RMB Billion)
Table 33.41 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Registration Year. Since 2020
Table 33.42 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2020
Table 33.43 Clinical Trial Analysis: Distribution by Trial Phase
Table 33.44 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 33.45 Clinical Trial Analysis: Distribution by Trial Status
Table 33.46 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Table 33.47 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Status
Table 33.48 Clinical Trial Analysis: Distribution by Target Patient Population
Table 33.49 Clinical Trial Analysis: Distribution by Patient Gender
Table 33.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 33.51 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Table 33.52 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Table 33.53 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 33.54 Clinical Trial Analysis: Distribution by Trial Purpose
Table 33.55 Most Active Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Table 33.56 Most Active Non-Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Table 33.57 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 33.58 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 33.59 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 33.60 Clinical Trial Analysis: Distribution of Clinical Trials by Geography, Trial Status and Trial Phase
Table 33.61 Adeno-associated Viral Vector Based Therapy Developers: Cumulative Year-wise Trend, since 2017
Table 33.62 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Type of Partnership
Table 33.63 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Partnership and Type of Partnership, since 2022
Table 33.64 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Partnership and Type of Partner, since 2022
Table 33.65 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Type of Partnership and Type of Partner
Table 33.66 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Therapeutic Area
Table 33.67 Most Active Players: Distribution by Number of Partnerships
Table 33.68 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Country
Table 33.69 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Region
Table 33.70 Adeno-associated Viral Vector Manufacturers: Cumulative Year-wise Trend, since 2017
Table 33.71 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partnership
Table 33.72 Adeno-associated Viral Vector Manufacturers: Distribution by Year and Type of Partnership, since 2022
Table 33.73 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Partnership and Type of Partner
Table 33.74 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partnership and Type of Partner
Table 33.75 Adeno-associated Viral Vector Manufacturers: Distribution by Therapeutic Area
Table 33.76 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Table 33.77 Most Active Players: Distribution by Number of Partnerships
Table 33.78 Adeno-associated Viral Vector Manufacturers: Distribution by Country
Table 33.79 Adeno-associated Viral Vector Manufacturers: Distribution by Region
Table 33.80 Patent Analysis: Distribution by Type of Patent
Table 33.81 Patent Analysis: Distribution by Patent Application Year, since pre-2019
Table 33.82 Patent Analysis: Distribution by Publication Year, since 2021
Table 33.83 Patent Analysis: Type of Patent and Publication Year
Table 33.84 Patent Analysis: Distribution by Patent Jurisdiction
Table 33.85 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, since 2021
Table 33.86 Leading Industry Players: Distribution by Number of Patents
Table 33.87 Leading Non-Industry Players: Distribution by Number of Patents
Table 33.88 Leading Patent Assignees: Distribution by Number of Patents
Table 33.89 Patent Valuation: Distribution of Patents by Age
Table 33.90 Adeno-associated Viral Vectors: Patent Valuation
Table 33.91 Start-up Health Indexing: Distribution by Location of Headquarters
Table 33.92 Start-up Health Indexing: Distribution by Pipeline Strength
Table 33.93 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 33.94 Start-up Health Indexing: Distribution by Indication Diversity
Table 33.95 Analysis of Start-ups: Distribution by Patent Strength
Table 33.96 Start-up Health Indexing: Distribution by Partnership Activity
Table 33.97 Global Adeno-associated Viral Vector Based Therapeutics Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Table 33.98 Global Adeno-associated Viral Vector Based Therapeutics Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Table 33.99 Global Adeno-associated Viral Vector Based Therapeutics Market Forecasted Estimates (till 2035) Optimistic Scenario (USD Million)
Table 33.100 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Therapeutic Area
Table 33.101 Adeno-associated Viral Vector Based Therapeutics Market for Muscle-related Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.102 Adeno-associated Viral Vector Based Therapeutics Market for Genetic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.103 Adeno-associated Viral Vector Based Therapeutics Market for Hematological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.104 Adeno-associated Viral Vector Based Therapeutics Market for Ophthalmic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.105 Adeno-associated Viral Vector Based Therapeutics Market for Dermatological Disorders, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.106 Adeno-associated Viral Vector Based Therapeutics Market for Metabolic Disorders, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.107 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Type of Therapy
Table 33.108 Adeno-associated Viral Vector Based Therapeutics Market for Gene Augmentation Therapy, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.109 Adeno-associated Viral Vector Based Therapeutics Market for Gene Regulation Therapy, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.110 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Route of Administration
Table 33.111 Adeno-associated Viral Vector Based Therapeutics Market for Intravenous Route, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.112 Adeno-associated Viral Vector Based Therapeutics Market for Subretinal Route, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.113 Adeno-associated Viral Vector Based Therapeutics Market for Intravitreal Route, Historical Trends (since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.114 Adeno-associated Viral Vector Based Therapeutics Market for Other Routes, Historical Trends (since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.115 Adeno-associated Viral Vector Based Therapeutics Market: Distribution by Geographical Regions
Table 33.116 Adeno-associated Viral Vector Based Therapeutics Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.117 Adeno-associated Viral Vector Based Therapeutics Market in Europe, Forecasted Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD
Table 33.118 Adeno-associated Viral Vector Based Therapeutics Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.119 Adeno-associated Viral Vector Based Therapeutics Market for Latin America and Rest of the World, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.120 Adeno-associated Vector Based Therapeutics Market: Luxturna Sales Forecast, till 2035 (USD Million)
Table 33.121 Adeno-associated Vector Based Therapeutics Market: Hemgenix Sales Forecast, till 2035 (USD Million)
Table 33.122 Adeno-associated Vector Based Therapeutics Market: Zolgensma Sales Forecast, till 2035 (USD Million)
Table 33.123 Adeno-associated Vector Based Therapeutics Market: Roctavian Sales Forecast, till 2035 (USD Million)
Table 33.124 Adeno-associated Vector Based Therapeutics Market: Elevidys Sales Forecast, till 2035 (USD Million)
Table 33.125 Adeno-associated Vector Based Therapeutics Market: Upstaza Sales Forecast, till 2035 (USD Million)
Table 33.126 Adeno-associated Vector Based Therapeutics Market: EB 101 Sales Forecast, till 2035 (USD Million)
Table 33.127 Adeno-associated Vector Based Therapeutics Market: BBM H901 Sales Forecast, till 2035 (USD Million)
Table 33.128 Adeno-associated Vector Based Therapeutics Market: AGTC 501 Sales Forecast, till 2035 (USD Million)
Table 33.129 Adeno-associated Vector Based Therapeutics Market: Lumevoq Sales Forecast, till 2025 (USD Million)
Table 33.130 Adeno-associated Vector Based Therapeutics Market: NFS-01 Sales Forecast, till 2035 (USD Million)
Table 33.131 Adeno-associated Vector Based Therapeutics Market: RGX-314 Sales Forecast, till 2035 (USD Million)
Table 33.132 Adeno-associated Vector Based Therapeutics Market: SPK-8011 Sales Forecast, till 2035 (USD Million)
Table 33.133 Adeno-associated Vector Based Therapeutics Market: Giroctocogene fitelparvovec Sales Forecast, till 2035 (USD Million)
Table 33.134 Adeno-associated Vector Based Therapeutics Market: RGX-121 Sales Forecast, till 2035 (USD Million)
Table 33.135 Adeno-associated Vector Based Therapeutics Market: DTx-401 Sales Forecast, till 2035 (USD Million)
Table 33.136 Adeno-associated Vector Based Therapeutics Market: DTx-301 Sales Forecast, till 2035 (USD Million)
Table 33.137 Adeno-associated Vector Based Therapeutics Market: ABO-102 Sales Forecast, till 2035 (USD Million)
Table 33.138 Adeno-associated Vector Based Therapeutics Market: AAV-RPE65 Sales Forecast, till 2035 (USD Million)
Table 33.139 Adeno-associated Vector Based Therapeutics Market: Ixoberogene Soroparvovec Sales Forecast, till 2035 (USD Million)
Table 33.140 Adeno-associated Vector Based Therapeutics Market: OCU400 Sales Forecast, till 2035 (USD Million)
Table 33.141 Global Adeno-associated Viral Vector Based Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Table 33.142 Global Adeno-associated Viral Vector Based Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Table 33.143 Global Adeno-associated Viral Vector Based Manufacturing Market Forecasted Estimates (till 2035) Optimistic Scenario (USD Million)
Table 33.144 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Stage of Development
Table 33.145 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.146 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.147 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.148 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Therapeutic Area
Table 33.149 Adeno-associated Viral Vector Based Manufacturing Market for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.150 Adeno-associated Viral Vector Based Manufacturing Market for Rare Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.151 Adeno-associated Viral Vector Based Manufacturing Market for Musculoskeletal Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.152 Adeno-associated Viral Vector Based Manufacturing Market for Genetic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.153 Adeno-associated Viral Vector Based Manufacturing Market for Hematological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.154 Adeno-associated Viral Vector Based Manufacturing Market for Neurological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.155 Adeno-associated Viral Vector Based Manufacturing Market for Metabolic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.156 Adeno-associated Viral Vector Based Manufacturing Market for Sensory Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.157 Adeno-associated Viral Vector Based Manufacturing Market for Ophthalmic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.158 Adeno-associated Viral Vector Based Manufacturing Market for Dermatological Disorders, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.159 Adeno-associated Viral Vector Based Manufacturing Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.160 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Geographical Regions
Table 33.161 Adeno-associated Viral Vector Based Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.162 Adeno-associated Viral Vector Based Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.163 Adeno-associated Viral Vector Based Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.164 Adeno-associated Viral Vector Based Manufacturing Market in Middle east and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.165 Adeno-associated Viral Vector Based Manufacturing Market in Latin America and Rest of the World, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.166 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Commercial, Clinical and Preclinical Stage Products
Table 33.167 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.168 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products: Distribution by Therapeutic Area
Table 33.169 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products: Distribution by Route of Administration
Table 33.170 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Stage Products: Distribution by Geographical Regions
Table 33.171 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.172 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products: Distribution by Phase of Development
Table 33.173 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products: Distribution by Therapeutic Area
Table 33.174 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Stage Products: Distribution by Geographical Regions
Table 33.175 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 33.176 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products: Distribution by Therapeutic Area
Table 33.177 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products: Distribution by Animal Model Used
Table 33.178 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Stage Products: Distribution by Geographical Region

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Astellas Pharma
Charles River Laboratories
Cytiva
Lonza
Patheon pharma services
Sanofi
WuXi AppTec
Sarepta Therapeutics
Uniqure
Spark Therapeutics
PTC Therapeutics
Biomarin Pharmaceutical
Novartis

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4236EUR$4,799USD£3,697GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6178EUR$6,999USD£5,392GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€15888EUR$17,999USD£13,866GBP

Global AAV Market: Growth and Trends

Global AAV Market: Key Insights

Report Scope:

Global AAV Market: Key Segments

Example Players in the AAV Market Profiled in the Report Include:

Global AAV Market: Research Coverage

Key Questions Answered in this Report

Reasons to Buy this Report

Additional Benefits

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Pipeline Insight, 2025

Drug and Gene Delivery Devices Market Report and Forecast 2025-2034

Gene Delivery Technologies Market - Global Forecast 2025-2030

Gene Delivery Technologies - Global Strategic Business Report

Drug and Gene Delivery Devices Market Report 2025